# ADRC Consortium for Clarity in ADRD Research Through Imaging

> **NIH NIH U01** · UNIVERSITY OF WISCONSIN-MADISON · 2024 · $29,557,545

## Abstract

PROJECT SUMMARY
Alzheimer’s disease (AD) pathophysiology seldom occurs in isolation, and it is widely established from the
neuropathology literature that the majority of individuals with dementia have multiple etiology dementia (MED).
MED is common but undetected in extant major cohort studies and treatment trials for AD; many studies
intentionally restrict clinical heterogeneity to an assumed single etiology by using narrowly defined clinical
enrollment criteria. A major gap in our field is the lack of validated tools to detect MED in-vivo. The next era of
large-scale imaging biomarker studies for AD and related disorders (ADRD) will require strategies commensurate
with the known but largely unaddressed problem of etiologic heterogeneity. The Alzheimer’s Disease Research
Centers (ADRCs) are uniquely positioned to meet this need. Collectively the 37 ADRCs follow ~14,000 active
enrollees with high brain donor and autopsy rates (>60%). The ADRCs recruit across the clinical severity
continuum and amply represent the several diseases comprising ADRD. Now, as a consortium, the centers will
conduct a uniform imaging protocol capable of elucidating individualized etiological profiles including
foundational PET imaging for AD proteinopathy (Amyloid and Tau), vascular burden with MRI and additional
structural MRI and FDG PET for assessing the several patterns of morphologic and metabolic
Neurodegeneration signatures of both AD and non-AD proteinopathies on deeply phenotyped patients. Design:
This is a longitudinal imaging study at 2-year intervals that is superimposed on and fully integrated with the
ongoing uniform cognitive and clinical data collection the 37 ADRCs already do. We will study 2,000
ethnoculturally diverse ADRC participants that are either clinically unimpaired (CU; N=800) or impaired
(N=1,200) where AD is a considered, though need not be the primary suspected etiology. Aim 1 creates the ATN
cohort through prospective imaging and plasma collection and establishes the foundational shared resource in
conjunction with the National Alzheimer’s Coordinating Center (NACC) with linkage to the vast clinical, cognitive,
and genetic datasets on these same participants. In Aim 2 we examine the temporal progression of the two most
common etiologies—AD and vascular disease. We examine onset ages and duration of each and their joint
effect on cognitive decline. Aim 3 focuses on other common proteinopathies. Classification and joint modelling
methods will be applied to estimate etiologic composition and the effect of multi-proteinopathy on clinical and
cognitive change. ATN imaging–a critical foundation for characterizing likely dementia etiologies—is needed on
this expertly-diagnosed, uniformly evaluated MED ADRD cohort where neuropathology can inform
clinicopathologic correlation, mechanistic underpinnings, and strategic diagnostic and therapeutic development.
The consortium of ADRCs have the expertise and capacity to conduct this study and will work t...

## Key facts

- **NIH application ID:** 10930139
- **Project number:** 5U01AG082350-02
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **Principal Investigator:** Sarah Biber
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $29,557,545
- **Award type:** 5
- **Project period:** 2023-09-15 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10930139

## Citation

> US National Institutes of Health, RePORTER application 10930139, ADRC Consortium for Clarity in ADRD Research Through Imaging (5U01AG082350-02). Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/grant/nih/10930139. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*